Is MacroGenics, Inc. (MGNX) a Buy, Sell, or Hold?
NASDAQ : MGNX
MacroGenics, Inc.
$4.485 USD
$0.36 (8.86%)
- Volume
- 379.93K
- Average Volume
- 1.14M
- Market Capitalization
- $285.08M
- P/E Ratio
- -4.08
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $5.08
- Year Low
- $1.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.90
| Source | Headline |
|---|---|
|
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 2026-07-02 13:01:09 |
|
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora. globenewswire.com - 2026-07-02 09:25:00 |
|
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration's (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes. globenewswire.com - 2026-06-22 16:43:00 |
|
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET. globenewswire.com - 2026-05-14 16:01:00 |
|
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago. zacks.com - 2026-05-13 18:36:10 |
|
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and highlighted its recent corporate progress. globenewswire.com - 2026-05-13 16:01:00 |
|
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
•MacroGenics to receive $122. 5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co. globenewswire.com - 2026-05-11 17:20:43 |
|
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora globenewswire.com - 2026-05-11 17:20:00 |
|
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2026-05-05 11:00:30 |
|
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million globenewswire.com - 2026-05-04 07:30:00 |
